A phase IIa randomized, double-blind trial of erlotinib in inhibiting epidermal growth factor receptor signaling in aberrant crypt foci of the colorectum
Daniel L. Gillen, Frank L. Meyskens, Timothy R. Morgan, Jason A. Zell, Robert Carroll, Richard Benya, Wen Pin Chen, Allen Mo, Chris Tucker, Asmita Bhattacharya, Zhiliang Huang, Myra Arcilla, Vanessa Wong, Jinah Chung, Rachel Gonzalez, Luz Maria Rodriguez, Eva Szabo, Daniel W. Rosenberg, Steven M. Lipkin
Dive into the research topics of 'A phase IIa randomized, double-blind trial of erlotinib in inhibiting epidermal growth factor receptor signaling in aberrant crypt foci of the colorectum'. Together they form a unique fingerprint.